Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Sarah Holstein
University of Nebraska Medical Center, Omaha, NE, USA
Dr Holstein, MD, PhD, is a professor in the Division of Oncology and Hematology at the University of Nebraska Medical Center, Omaha, NE, USA. She is the team leader of the Myeloma/Plasma Cell Dyscrasia Group at the Fred and Pamela Buffett Cancer Center. Dr Holstein previously served as a myeloma specialist at the University of Iowa and the Roswell Park Comprehensive Cancer Center, New York, USA. She is a physician-scientist, whose basic science, translational and clinical research focuses on myeloma. read more
Dr Holstein serves on multiple national myeloma committees and is a member of the International Myeloma Working Group. She has published more than 100 peer-reviewed articles and multiple book chapters. She serves as an associate editor for Clinical Pharmacology & Therapeutics, as well as the British Journal of Haematology.
Dr Sarah Holstein discloses: Consultancy fees from AbbVie, Bristol Myers Squibb, Janssen Pharmaceuticals, Oncopeptides, Secura Bio and Takeda Pharmaceutical (relationships terminated); Grants/research support from Bristol Myers Squibb and Oncopeptides (relationships terminated).
Dr Nikhil Munshi
Dana-Farber Cancer Institute,
Boston, MA, USA
Dr. Munshi, MD, is professor of medicine at Harvard Medical School, as well as the endowed Kraft Family Chair, director of basic and correlative science and associate director of the Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute. He is a senior physician at the Brigham and Women’s Hospital and the Boston VA Healthcare System. Dr Munshi received his medical degree from the SSG Hospital and MS University, Baroda, India. He completed a research fellowship in medical oncology at the Johns Hopkins Oncology Center in Baltimore, MA, USA and a clinical fellowship in haematology/oncology at the Indiana University Medical Center, IN, USA. read more
Dr Munshi’s research has aimed to understand genomic changes in myeloma, elucidate molecular mechanisms driving the genomic instability in cancer, and improve diagnosis, prognosis and therapeutics. His current research centres on integrative oncogenomics in myeloma and developing novel targeted therapeutics including antigen-directed and immune effector cell therapy/vaccine approaches.
Dr Munshi has over 500 peer-reviewed publications and has mentored over 70 junior faculty, post-doctoral fellows, and students. Dr Munshi is the president of the International Myeloma Society and an associate editor for Blood Advances. He has received several awards, including the prestigious Waldenström Lifetime Achievement Award for his contribution to myeloma research and the Dr BC Roy National Award by the president of India.
Dr Nikhil Munshi discloses: Consultancy fees from Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, Legend Biotech, Novartis, OncoPep, Pfizer and Takeda Pharmaceutical (all relationships terminated); Stock/shareholder (self-managed) OncoPep.
Dr Noopur Raje
Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Dr Raje is a professor of medicine at Harvard Medical School, the director of the Center for Multiple Myeloma and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. She is a physician scientist with a primary focus on multiple myeloma and related plasma cell disorders. read more
Dr Raje has focused on developing new promising therapies for multiple myeloma. Her laboratory efforts are aimed at identifying cellular signalling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and designing trials to specifically harness these. She is the co-chair of the National Cancer Institute steering committee for multiple myeloma and a board member of the International Myeloma Society.
Dr Noopur Raje discloses: Advisory board or panel fees from Caribou Biosciences and Immuneel Therapeutics; Consultancy fees from AbbVie, Amgen, Bristol Myers Squibb, Pfizer, Sanofi and Takeda Pharmaceutical; Grants/research support from Bluebird Bio.
